More NewsCDS Sentiment Shows Backing for AstraZeneca in Pfizer Takeover Battle

CDS Sentiment Shows Backing for AstraZeneca in Pfizer Takeover Battle

Pfizer’s £63bn bid to takeover UK pharmaceutical firm AstraZeneca has led to a 21% tightening of the latter’s credit default swap (CDS) position on global markets as it promotes higher revenue targets as part of its defence, says Fitch, while conversely Pfizer’s CDS position has widened 28% amid fears that it may take on too much debt to facilitate the deal.

In a CDS case study research note showing the respective pharmaceutical giants positions during May on Fitch Solutions CDS Pricing Service benchmark, the ratings agency’s tech and modelling unit has drawn some conclusions about market sentiment over Pfizer and AstraZeneca’s creditworthiness and what this might mean for the future ratings of the pharma firms.

According to Fitch Solutions its CDS assessment service provides credit risk indicators that are designed to provide real-time, market-based views of creditworthiness. As such, the firms claims its pricing information can and often does reflect more short term market views and be indicative of market sentiment in cases such this. This is in contrast to the ratings agency’s Issuer Default Ratings (IDRs), which are based on a more forward-looking fundamental credit analysis over an extended period of time.

“Credit protection for both pharmaceutical giants is still pricing strong, though market sentiment appears to be improving for AstraZeneca and souring for Pfizer,” said Fitch Solutions’ director, Diana Allmendinger, in the note.

“Part of the reason may be that AstraZeneca has announced aggressive revenue targets in an effort to ward off a potential Pfizer takeover,” speculated Allmendinger, while conversely, “the markets are anticipating that Pfizer would likely have to take on debt to acquire AstraZeneca, which would stress its leverage ratios.”

If Pfizer’s second £63bn contested bid to takeover AstraZeneca is ultimately successful it would be the biggest takeover in UK corporate history. It has led to questions in Parliament and in the US about the tax regime Pfizer would benefit from – with the lower 20% corporation tax in the UK thought to be one of the drivers for the deal – and about where its research and scientific activities would be carried out.

Related Articles

Infosys Finacle to power Santander UK’s international cash management system

More News Infosys Finacle to power Santander UK’s international cash management system

2m The Global Treasurer
Preparing for GDPR? Here’s four things to consider

More News Preparing for GDPR? Here’s four things to consider

5m Elliott Wiseman
Cash flow in focus for investors

Cash Management Cash flow in focus for investors

6m Conor Deegan
Treasury TV: Karen Pugsley, Domino's Pizza Group

More News Treasury TV: Karen Pugsley, Domino's Pizza Group

6m Victoria Beckett
Treasury TV: Yeng Butler compares US and European MMF reforms

Compliance Treasury TV: Yeng Butler compares US and European MMF reforms

6m Victoria Beckett
Treasury TV: Tim de Knegt, The Port of Rotterdam

10 Minutes With The Treasury Treasury TV: Tim de Knegt, The Port of Rotterdam

6m Victoria Beckett
Banks are selling clients short with short dated cash deposit U-turns

Banking Banks are selling clients short with short dated cash deposit U-turns

6m Victoria Beckett
What does sterling’s Brexit boost mean for UK manufacturers?

More News What does sterling’s Brexit boost mean for UK manufacturers?

7m Tasja Botha